SGD Pharma’s CEO, Olivier Rousseau, reflects on a 2025 marked by challenges, progress and strong collective achievements.
Sustainability: SGD Pharma has set ambitious targets. A 42 percent reduction of CO2 emissions between 2022 and 2030, validated by SBTi. The company is proud to have earned Platinum status from EcoVadis in 2025, a recognition that places us among the 1 percent top-performing glass manufacturers worldwide in terms of ESG practices. In 2026, the company will build its first hybrid furnace.
Operational excellence: strong performances across several Business Units and industrial sites, supported by a record level of CAPEX to modernise SGD Pharma’s furnaces and production lines.
Growth & innovation: the launch of new solutions, the acceleration of the global tubular business and the acquisition of Alphial, strengthening the company leadership in glass ampoules and RTU vials.
SGD Pharma strategy is moving forward, the teams are fully engaged and 2026 is shaping up to be another important milestone for the company.